| Introduction

Genomic instability resulting from homologous recombination DNA repair deficiency (HRD) is a response biomarker to assess ovarian and breast cancer patient eligibility for PARP inhibitor and platinum-based therapies. 

GeneWell offers single and tumour-normal matched gDNA reference standards, which contributes to the promise of precise treatment. Our HRD standards are cell line derived to mimic clinical samples and verified by Myriad myChoice CDx panel and GW self developed HRD analysis process to provide reference HRD status and scores. They are ideal for assay development, performance validation, routine quality control, and fine tuning of HRD bioinformatic analysis process. These standards come in gDNA format and can also be customised for various formats and tumour fractions.

| Key Features

● Designed for quality control of HRD assay process

● The HRD scores are calculated by proprietary algorithm of Myriad myChoice^® CDx

● The HRD scores of reference standards cover positive & negative HRD status (GIS ≥ 42 confers a positive GIS status)

● Evaluate the workflow of tumor sample HRD status determination

| Applications

The series of HRD reference standards is used to monitor the performance of your assay, and validate  the precision of your workflow.

| Product List

Made-to-order Product List

Customised Product List

| Resources

HRD reference standards-Flyer

HRD gDNA Reference Standards-Package Insert.pdf